{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:12:32Z","timestamp":1791087152105,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41433-025-04175-5","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T13:25:49Z","timestamp":1766496349000},"page":"293-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteomic profile of faricimab-associated occlusive retinal vasculitis"],"prefix":"10.1038","volume":"40","author":[{"given":"Jia-Horung","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishaan","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng Xian","family":"Thng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6404-5244","authenticated-orcid":false,"given":"Nathan","family":"Shows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Yavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mitsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey A.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Leib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo Galindo","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur Sudhir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"El Feky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc Trong Tuong","family":"Than","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Akhavanrezayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Mobasserian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2907-0050","authenticated-orcid":false,"given":"Osama","family":"Elaraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-6941","authenticated-orcid":false,"given":"Jonathan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-8441","authenticated-orcid":false,"given":"Quan","family":"Dong Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"4175_CR1","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cells9081869","volume":"9","author":"M Khan","year":"2020","unstructured":"Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells. 2020;9:1869.","journal-title":"Cells"},{"key":"4175_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin AJ, Hahn P, Murray TG, Arevalo JF, Blinder KJ, Choudhry N, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretina Dis. 2020;4:269\u201379.","journal-title":"J Vitreoretina Dis"},{"key":"4175_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100989","volume":"20","author":"PG Iyer","year":"2020","unstructured":"Iyer PG, Peden MC, Su\u00f1er IJ, Patel N, Dubovy SR, Albini TA. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep. 2020;20:100989.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4175_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamaophthalmol.2020.2810","volume":"138","author":"SSA Kondapalli","year":"2020","unstructured":"Kondapalli SSA. Retinal vasculitis after administration of brolucizumab resulting in severe loss of visual acuity. JAMA Ophthalmol. 2020;138:1103\u20134.","journal-title":"JAMA Ophthalmol"},{"key":"4175_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100680","volume":"18","author":"SJ Haug","year":"2020","unstructured":"Haug SJ, Hien DL, Uludag G, Ngoc TTT, Lajevardi S, Halim MS, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4175_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687","volume":"18","author":"A Jain","year":"2020","unstructured":"Jain A, Chea S, Matsumiya W, Halim MS, Ya\u015far \u00c7, Kuang G, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4175_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"4175_CR8","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20136 month results. Eye. 2023;37:3574\u201381.","journal-title":"Eye"},{"key":"4175_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155\u201370.","journal-title":"Ophthalmology"},{"key":"4175_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"4175_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/jamaophthalmol.2024.0928","volume":"142","author":"Y Li","year":"2024","unstructured":"Li Y, Chong R, Fung AT. Association of occlusive retinal vasculitis with intravitreal faricimab. JAMA Ophthalmol. 2024;142:489\u201391.","journal-title":"JAMA Ophthalmol"},{"key":"4175_CR12","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","volume":"142","author":"M Cozzi","year":"2024","unstructured":"Cozzi M, Ziegler A, Fasler K, Muth DR, Blaser F, Zweifel SA. Sterile intraocular inflammation associated with faricimab. JAMA Ophthalmol. 2024;142:1028\u201336.","journal-title":"JAMA Ophthalmol"},{"key":"4175_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/24741264231220224","volume":"8","author":"AJ Witkin","year":"2024","unstructured":"Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee. J Vitreoretin Dis. 2024;8:9\u201320.","journal-title":"J Vitreoretin Dis"},{"key":"4175_CR14","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3390\/jcm11092525","volume":"11","author":"A Agarwal","year":"2022","unstructured":"Agarwal A, R\u00fcbsam A, Zur Bonsen L, Pichi F, Neri P, Pleyer U. A Comprehensive update on retinal vasculitis: etiologies, manifestations and treatments. J Clin Med. 2022;11:2525.","journal-title":"J Clin Med"},{"key":"4175_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000119871","volume":"40","author":"RR Caspi","year":"2008","unstructured":"Caspi RR, Silver PB, Luger D, Tang J, Cortes LM, Pennesi G, et al. Mouse models of experimental autoimmune uveitis. Ophthalmic Res. 2008;40:169\u201374.","journal-title":"Ophthalmic Res"},{"key":"4175_CR16","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1002\/eji.201444671","volume":"44","author":"M Barbour","year":"2014","unstructured":"Barbour M, Allan D, Xu H, Pei C, Chen M, Niedbala W, et al. IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol. 2014;44:3320\u20139.","journal-title":"Eur J Immunol"},{"key":"4175_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.exer.2005.07.011","volume":"82","author":"RW Read","year":"2006","unstructured":"Read RW, Szalai AJ, Vogt SD, McGwin G, Barnum SR. Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. Exp Eye Res. 2006;82:389\u201394.","journal-title":"Exp Eye Res"},{"key":"4175_CR18","first-page":"213","volume":"34","author":"RC Gupta","year":"1978","unstructured":"Gupta RC, O\u2019Duffy JD, McDuffie FC, Meurer M, Jordon RE. Circulating immune complexes in active Beh\u00e7et\u2019s disease. Clin Exp Immunol. 1978;34:213\u20138.","journal-title":"Clin Exp Immunol"},{"key":"4175_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.705796","volume":"8","author":"AM Abu El-Asrar","year":"2021","unstructured":"Abu El-Asrar AM, Van Damme J, Struyf S, Opdenakker G. New perspectives on the immunopathogenesis and treatment of uveitis associated with Vogt-Koyanagi-Harada disease. Front Med. 2021;8:705796.","journal-title":"Front Med"},{"key":"4175_CR20","first-page":"690","volume":"93","author":"CC Chan","year":"1986","unstructured":"Chan CC, Nussenblatt RB, Fujikawa LS, Palestine AG, Stevens G Jr., Parver LM, et al. Sympathetic ophthalmia. Immunopathol Find Ophthalmol. 1986;93:690\u20135.","journal-title":"Immunopathol Find Ophthalmol"},{"key":"4175_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5241","volume":"15","author":"AC Karle","year":"2023","unstructured":"Karle AC, Wrobel MB, Koepke S, Gutknecht M, Gottlieb S, Christen B, et al. Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis\/retinal vascular occlusion adverse events. Sci Transl Med. 2023;15:eabq5241.","journal-title":"Sci Transl Med"},{"key":"4175_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5068","volume":"15","author":"JD Kearns","year":"2023","unstructured":"Kearns JD, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, et al. A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab. Sci Transl Med. 2023;15:eabq5068.","journal-title":"Sci Transl Med"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04175-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:06:32Z","timestamp":1770372392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04175-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04175-5","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}